Join the PharmaVoice and BioPharma Dive editorial teams for an exclusive event where our journalists will speak with top executives and experts to discuss the state of cancer drug research, its evolution and development.
This event will provide expert perspectives on the trends shaping oncology. Attendees will gain firsthand insights into the industry’s pipeline strategies, key takeaways from the American Society of Clinical Oncology’s annual meeting and the growing role of China-based drug developers.
What to expect:
- One-on-one discussions with industry leaders spotlighting pipeline strategies for antibody-drug conjugates and immunotherapies
- Expert panel discussions on the most consequential ASCO data and how it may shift cancer research and treatment
- A panel discussion on the role of China-based drug companies and their influence in the field
Who should attend?
- Executives and employees at oncology-focused companies
- Cancer researchers and physicians, especially those following the 2025 ASCO meeting
- Partners and associates at venture capital firms
- Other professionals in the biopharma and healthcare space
Reserve Your Spot Today!
Reserve Your Seat
Agenda
This event will feature two fireside chats and two panels featuring Dive journalists and leading executives and experts from key companies in the oncology field. Topics covered will include antibody-drug conjugates, data from the 2025 ASCO meeting, emerging cancer drugs and more. Specific times for each session to be announced soon.
